All In Biotech

Drug Trial Radar · NCT00946712

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: May 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,333 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,333

Actual

Start

Jul 15, 2009

Primary completion

Aug 31, 2017

Study completion Feb 8, 2022

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jul 27, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or non-small cell lung cancer that has returned after a period of improvement (recurrent). Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may prevent the growth of new blood vessels that tumor needs to grow. Cetuximab may also stop cancer cells from growing by binding and interfering with a protein on the surface of the tumor cell that is needed for tumor growth. It is not yet known whether giving carboplatin and paclitaxel are more effective with or without bevacizumab and/or cetuximab in treating patients with non-small cell lung cancer.

Conditions

  • Recurrent Large Cell Lung Carcinoma
  • Recurrent Lung Adenocarcinoma
  • Recurrent Squamous Cell Lung Carcinoma
  • Stage IV Large Cell Lung Carcinoma
  • Stage IV Lung Adenocarcinoma
  • Stage IV Squamous Cell Lung Carcinoma

Interventions

  • BevacizumabBiological

    Given IV

  • CarboplatinDrug

    Given IV

  • CetuximabBiological

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PaclitaxelDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in the Entire Study PopulationTime frame: Patients will be followed every 3 weeks while on protocol treatment. Once off all protocol treatment, patients will be followed every 6 months until death or up to 3 years
  2. Progression-free Survival (PFS) of EGFR FISH-positive Patients by Institutional ReviewTime frame: Disease assessment will be repeated every 6 weeks for the first 9 months and every 3 months thereafter, until disease progression.

Locations

798 sites in 2 countries. Site status is shown where the registry gives one.

  • Northeast Alabama Regional Medical Center

    Anniston, Alabama

  • Gulf Coast MBCCOP

    Mobile, Alabama

  • Providence Hospital

    Mobile, Alabama

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • The University of Arizona Cancer Center-Orange Grove Campus

    Tucson, Arizona

  • The University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • The University of Arizona Medical Center-University Campus

    Tucson, Arizona

  • Fowler Family Center for Cancer Care

    Jonesboro, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • East Bay Medical Oncology Hematology Medical Associates-Antioch

    Antioch, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Mills - Peninsula Hospitals

    Burlingame, California

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Valley Medical Oncology Consultants-Castro Valley

    Castro Valley, California

  • Enloe Medical Center

    Chico, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Epic Care-Dublin

    Dublin, California

  • Bay Area Breast Surgeons Inc

    Emeryville, California

  • Epic Care Partners in Cancer Care

    Emeryville, California

  • Northbay Cancer Center

    Fairfield, California

  • Valley Medical Oncology Consultants-Fremont

    Fremont, California

  • Marin General Hospital

    Greenbrae, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Los Angeles County-USC Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • Mather Veteran Affairs Medical Center

    Mather, California

  • Mercy UC Davis Cancer Center

    Merced, California

  • Memorial Medical Center

    Modesto, California

  • El Camino Hospital

    Mountain View, California

  • Sutter Cancer Research Consortium

    Novato, California

Showing 40 of 798 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.